A great meeting, proud to be part of the amazing faculty and happy to share our experience #MPNsm Ruben A. Mesa, MD Abdulraheem Yacoub Harry Gill, MD FRCP FRCPath
👉👉👉Congratulations Dr Ruben Mesa .Ruben A. Mesa, MD ! mcb.illinois.edu/news/2024-04-0… || #MPNSM Heme Reports MPNCo&D Congress Claire Harrison J.J. Kiladjian Adam Mead Vikas Gupta Harry Gill, MD FRCP FRCPath Nicole Kucine, MD,MS
Grateful to Dr Gill Harry Gill, MD FRCP FRCPath HKU Medicine for highlighting in his Commentary article our British Journal of Haematology finding of a DNA #methylation signature that predicts response to hypomethylating agents in #MDS
YD Vįčtør erika (taylors version) 🩷 Mojo Aman Khan MitchyMich Ryan Hill عمر بن عبدالعزيز Omar Abdulaziz Bru Daemon Sadiablo Stepping Back and Observing alef !¡ 🍉 Harry Gill, MD FRCP FRCPath Soca Calypso songs from the big vitchair Alberto Flores Halil İbrahim Yüksek Rana Sahib Phillip Lancaster حسين الغامدي
Next up Harry Gill, MD FRCP FRCPath on MF combinations! (A great teaser for MPN oral sessions this afternoon)
Congress | #EHA2023 Harry Gill, MD FRCP FRCPath HKU Medicine discusses a multicenter phase II study where an entirely oral AAA-based induction regimen in a risk-adapted strategy that minimized chemotherapy was effective and safe in patients with ND APL across all risk categories and ages. #leusm
Harry Gill, MD FRCP FRCPath And Jeanne M Palmer wrapping up the session with allo-HCT considerations in MF
#ASH23 | #ASHKudos to Ann Brazeau & MPN Ad&Ed Int'l team for helping us to raise awareness about MPNs over the years! Great job 👏! Great interview about future of our #MPNSM field ! Ruben A. Mesa, MD Aaron Gerds MD, MS Claire Harrison J.J. Kiladjian Nicole Kucine, MD,MS Harry Gill, MD FRCP FRCPath Dr Deepti Radia 🙌
CONGRESS| #EHA2023 Harry Gill, MD FRCP FRCPath HKU Medicine discusses the efficacy and safety of interferon alfa-2b in pts with pre fibrotic and low/intermediate risk MF. Responses in Hb, WBC and platelet counts were 76.6%, 87.2% and 78.7%, respectively. #MPN #MPN sm #medicalcongress
Ropeginterferon alfa 2b was “generally well tolerated” and induced molecular responses in patients with lower-risk early or prefibrotic stage PMF who had a JAK2 V617F mutation, according to a study by Harry Gill, MD FRCP FRCPath of HKU Medicine and colleagues.
📚buff.ly/44WWHyT
Huge congratulations my friend #SergeVerstovsek on your well earned retirement and exciting next step in your journey to cure #MPNs MPN Research Foundation MPN_Hub Global MPN Scientific Foundation MPNAdvocatesNetwork MPN Ad&Ed Int'l Harry Gill, MD FRCP FRCPath Claire Harrison J.J. Kiladjian Aaron Gerds MD, MS Stephen Oh MD Anderson Cancer Center Angela Fleischman MPNCo&D Congress
Come Join Our Medical Team at HKU Medicine – Hear from our clinical professoriates Dr. Gordon Wong, Dr Harry Gill, MD FRCP FRCPath, Dr. Aya Helali MD PhD and Dr. Dr Siddharth Sridhar #hkumed
youtube.com/watch?v=oU9UJq…
The all-oral regimen of arsenic trioxide, all-trans retinoic acid and ascorbic acid produced high 3-year overall survival and relapse-free survival rates in patients with acute promyelocytic leukemia. Harry Gill, MD FRCP FRCPath HKU Medicine ASH #ASH23 #leusm onclive.com/view/all-oral-…
Harry Gill, MD FRCP FRCPath Hello Dr Gill, good to know that there Asian group also very active for MPN I would love to participate and join this group
